Responses: patient examples. (A) Flow cytometric CRc in patients #14 and #37. Pretreatment (left panels) bone marrow aspirates demonstrated ALL blasts expressing abnormally bright CD20 and CD10. Posttreatment (right panels) bone marrow aspirates demonstrated only pre–B cells with a normal maturation profile based on CD20 and CD10 expression. Both patients achieved CRc (#14, CR; #37, CR incomplete blood count recovery [CRi]) after cycle 1 and were MRD negative after cycle 2. The limit of detection for this assay was 0.004%. (B) Patient #2: pretreatment (left panel) and posttreatment (right panel) bone marrow biopsies revealed decreased blast infiltration with 1 cycle of therapy (original magnification ×100; hematoxylin and eosin stain). Patient achieved PR after cycle 1 and CRi after cycle 2. (C) Patient #22: pretreatment (left panel) and posttreatment (right panel) fluorodeoxyglucose positron emission tomography scans show marked reduction in areas of uptake after 2 cycles of therapy.